Fibrin sealant in orthopedic surgery.
The use of clotting substances from blood for hemostasis dates back to 1909. In 1972, modern fibrin sealing (FS) was developed in Vienna. For application, the two components, i.e., a sealer protein solution (mainly fibrinogen) and a thrombin solution, are mixed to produce the fibrin clot. The sealant may be applied with a needle, as a spray, or by premixing (e.g., with antibiotics, bone chips) for subsequent sealant application in cavities. While the positive effect of FS in normal wound healing has been conclusively demonstrated, its influence on bone healing remains controversial. The positive experimental results mostly refer to the early phase of bone healing in rabbits (cortical drill hole, autologous and heterologous (Kiel) cancellous transplants, osteotomies, osteochondral fractures) and dogs (cortical bone and spongiosa defects). Some authors observed no effects (in dogs, osteotomy) or delayed healing in artificial bone growth chambers with the use of heterologous sealant. FS was also applied in combination with implantation material (tricalcium phosphate and bone gelatin) to facilitate application. Clinical results are especially convincing as to osteochondral fractures, repair of the Achilles tendon, and in hemophiliacs. Fibrin sealant facilitates hemostasis, permits tissue fixation, enhances plasticity of granular implant material, and stimulates fibroblast growth. Although its direct osteogenic effect remains questionable, fibrin sealant is known to be an excellent tool in orthopedic and trauma surgery.
D000818:Animals; D007611:Aprotinin / Q000008:administration & dosage / Q000627:therapeutic use*; D001842:Bone and Bones / Q000187:drug effects / Q000502:physiology; D002356:Cartilage / Q000187:drug effects; D004285:Dogs; D004338:Drug Combinations / Q000008:administration & dosage / Q000627:therapeutic use; D005176:Factor XIII / Q000008:administration & dosage / Q000627:therapeutic use*; D005337:Fibrin / Q000627:therapeutic use; D015718:Fibrin Tissue Adhesive; D005340:Fibrinogen / Q000008:administration & dosage / Q000627:therapeutic use*; D050723:Fractures, Bone / Q000188:drug therapy; D006467:Hemophilia A / Q000150:complications; D006470:Hemorrhage / Q000188:drug therapy / Q000209:etiology; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D011817:Rabbits; D013708:Tendon Injuries / Q000188:drug therapy; D013917:Thrombin / Q000008:administration & dosage / Q000627:therapeutic use*; D014014:Tissue Adhesives / Q000627:therapeutic use*; D014945:Wound Healing / Q000187:drug effects
D004338:Drug Combinations; D015718:Fibrin Tissue Adhesive; D014014:Tissue Adhesives; D005337:Fibrin; D005340:Fibrinogen; D005176:Factor XIII; D007611:Aprotinin; D013917:Thrombin